Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Janssen Research & Development, LLC
Peking University Shenzhen Hospital
Lung Cancer Group Cologne
University Health Network, Toronto